文献速递胸部肿瘤

国家癌症研究所-国际肺癌研究协会-间皮瘤应用研究基金会联合工作组提出的恶性胸膜间皮瘤手术为基础治疗标准化系统

A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Taskforce.
PubMed 文献 · J Thorac Oncol · 2019-05-25

该文源自2017年3月在NIH召开的间皮瘤临床试验规划会议联合工作组,针对恶性胸膜间皮瘤手术为基础的多模式治疗,提出统一手术方式并设计数据收集表和切除完整性评分系统,以促进患者选择和手术标准化,目标是在维持生活质量同等优先的前提下延长生存。

要点

  • 恶性胸膜间皮瘤仍不可治愈,需临床试验推进;部分特定亚组患者可从手术为基础的多模式治疗获益。
  • 因无法达到显微镜下完全切除,单纯手术似无作用;需试验确定哪些辅助治疗最佳增强手术的减瘤效果。
  • 作者提出统一手术方式和数据收集表及切除完整性评分系统,以利手术系列间比较和评估辅助治疗影响。

核心结论

  • 恶性胸膜间皮瘤仍被视为不可治愈,亟需临床试验以取得进展;虽非标准治疗,但有令人信服的证据表明特定亚组患者可从手术为基础的多模式治疗中获益。
  • 由于间皮瘤无法实现显微镜下完全切除,单纯手术似无作用;手术为基础治疗的显著进展将需要试验来确定哪些辅助治疗最佳增强手术的减瘤效果。

研究设计与样本

  • 本文为国家癌症研究所-国际肺癌研究协会-间皮瘤应用研究基金会联合工作组在2017年3月于NIH召开的间皮瘤临床试验规划会议上形成的联合成果。
  • 文章提出统一手术方式的建议,并提出一系列可立即采用的数据收集表,以及一个从手术数据表生成切除完整性评分的分级系统。

主要发现

  • 保留肺的手术方式在国际上正成为该癌症的主要切除手术,但各中心做法差异很大;牺牲肺的手术则相对标准化。
  • 目前无法严格评估辅助治疗联合手术的贡献,原因包括减瘤手术方式、癌症本身、患者选择、复发治疗及随访计划的高度变异性。

关键数值与推荐

  • 文章提出了一个分级系统,利用手术过程数据表的信息生成切除完整性评分,作为间皮瘤手术的共同分母。
  • 文章提出了系列数据收集表,可立即采用,旨在收集促进患者选择和确定间皮瘤手术哪些方面可且应标准化的必要信息。

临床怎么用

  • 作者建议采用更统一的手术方式,并立即采用所提出的数据收集表,以促进患者选择和确定间皮瘤手术可且应标准化的方面。
  • 作者提出利用手术数据表生成切除完整性评分,目标是延长生存同时将维持生活质量作为同等优先事项。

局限性

  • 原文指出目前无法严格评估辅助治疗联合手术的贡献,原因包括减瘤手术方式、癌症本身、患者选择、复发治疗及随访计划的高度变异性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This article is a joint effort arising from a task force formed at a National Cancer Institute-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Mesothelioma Clinical Trials Planning Meeting, held at the NIH in March 2017. Malignant pleural mesothelioma remains one of the most virulent and recalcitrant malignancies, still considered incurable, and in desperate need of clinical trials in order to make progress for our patients. Although not standard of care, there is compelling evidence that a select subgroup of mesothelioma patients benefit from a surgery-based multimodal approach. As it is not possible to achieve a microscopically complete resection with mesothelioma, there appears to be no role for surgery alone. Thus, it is anticipated that significant strides in the surgery-based treatment of this cancer will require trials that determine which complementary treatments best augment the cytoreductive efficacy of surgery. Although lung-sacrificing surgery for mesothelioma is fairly standardized, approaches to lung-sparing surgery are highly variable and lung sparing surgery is emerging internationally as the dominant extirpative procedure for this cancer. It is not currently possible to rigorously assess the contribution of the adjuvant treatments combined with surgery because of the variability in procedures used to debulk this cancer, the extreme variability of the cancer itself, the variability in patient selection, the variability in treatment of the inevitable recurrence, and even the variability in follow up schedules. This article is an effort to address these problems by suggesting a more uniform approach to the surgical procedure and also proposing a series of data collection forms that could be adopted immediately, with any eye toward collecting the information that will be necessary to facilitate patient selection and determine which aspects of mesothelioma surgery can and should be standardized - with the goal being extension of life while maintaining quality of life as an equal priority. Furthermore, a completely original contribution in this manuscript is the proposal of a grading system that takes the information from the surgical procedure data forms and generates a completeness of resection score. This is the initial effort to establish a common denominator for mesothelioma surgery that will allow for more accurate comparison between surgical series and better assessment of the impact of the treatments combined with surgery.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Friedberg JS, Culligan MJ, Tsao AS, et al. A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Taskforce. J Thorac Oncol. 2019. PMID: 31136816. doi:10.1016/j.jtho.2019.04.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。